

Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

<https://marketpublishers.com/r/I68031F9ED84EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: I68031F9ED84EN

Abstracts

The 7 major Idiopathic Pulmonary Fibrosis (IPF) markets reached a value of US\$ 3,586.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 6,906.1 Million by 2034, exhibiting a growth rate (CAGR) of 6.1% during 2024-2034.

Idiopathic Pulmonary Fibrosis (IPF) market is currently driven by factors such as a rising geriatric population, cigarette smoking, a strong drug pipeline that have a good efficacy and safety profile and improving diagnosis and drug treatment rates. Idiopathic Pulmonary Fibrosis represents the most common of the idiopathic interstitial pneumonias and is characterized by a chronic, progressive, fibrotic interstitial lung disease having an unknown cause. This disease rarely occurs before the age of 50 years and primarily affects older adults (60+). With the geriatric population expected to increase considerably over the long term, we expect the incidence of Idiopathic Pulmonary Fibrosis to increase significantly over the next few years.

In patients with IPF, the tiny air sacs in the lungs (alveoli) get damaged and increasingly scarred. This results in the lungs becoming stiff that makes it hard for oxygen to get into the blood. The causes of IPF are unknown, but various risk factors have been identified, this includes older age, cigarette smoking, environmental exposures, certain infections, etc. Cigarette smoking, particularly involving more than 20 pack-years, represents the most strongly associated environmental risk factor. Furthermore, heightened risk for IPF has been associated with various environmental exposures (metal dusts, automobile emissions, and wood dust). Occupations such as agriculture and managing livestock have also been associated with IPF. There is a high unmet need for novel therapies to treat IPF as conventional drugs has limited efficacy or an unfavorable safety profile.

IMARC Group's new report "Idiopathic Pulmonary Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Idiopathic Pulmonary Fibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Idiopathic Pulmonary Fibrosis market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Idiopathic Pulmonary Fibrosis across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Idiopathic Pulmonary Fibrosis and represents the largest market for Idiopathic Pulmonary Fibrosis treatment. Furthermore, the current Idiopathic Pulmonary Fibrosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Idiopathic Pulmonary Fibrosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, Current, and Future Epidemiology Scenario

Historical, Current, and Future Performance of the Idiopathic Pulmonary Fibrosis Market

Historical, Current, and Future Performance of Various Therapeutic Categories in the Idiopathic Pulmonary Fibrosis Market

Sales of Various Drugs Across the Idiopathic Pulmonary Fibrosis Market

Reimbursement Scenario in the Idiopathic Pulmonary Fibrosis Market

Competitive Landscape:

This report also provides a detailed analysis of the current Idiopathic Pulmonary Fibrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the Idiopathic Pulmonary Fibrosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?

What was the country-wise size of the Idiopathic Pulmonary Fibrosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Idiopathic Pulmonary Fibrosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the Idiopathic Pulmonary Fibrosis market?

Epidemiology Insights

What is the size of the Idiopathic Pulmonary Fibrosis patient pool (2018-2023) across

the seven major markets?

What would be the forecasted patient pool (2024-2034) of Idiopathic Pulmonary Fibrosis across the seven major markets?

What are the key factors driving the epidemiological trend of Idiopathic Pulmonary Fibrosis?

What will be the growth rate of Idiopathic Pulmonary Fibrosis patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current marketed Idiopathic Pulmonary Fibrosis drugs and what are their market performance?

What are the key pipeline Idiopathic Pulmonary Fibrosis drugs and how are they expected to perform in the coming years?

How safe are the currently marketed Idiopathic Pulmonary Fibrosis drugs and what are their efficacies?

How safe are the late-stage pipeline Idiopathic Pulmonary Fibrosis drugs and what are their efficacies?

What are the current treatment guidelines for Idiopathic Pulmonary Fibrosis drugs across the seven major markets?

Who are the key companies in the Idiopathic Pulmonary Fibrosis market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Idiopathic Pulmonary Fibrosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 IDIOPATHIC PULMONARY FIBROSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.3 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.4 Competitive Intelligence

5 IDIOPATHIC PULMONARY FIBROSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 IDIOPATHIC PULMONARY FIBROSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

8 IDIOPATHIC PULMONARY FIBROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Idiopathic Pulmonary Fibrosis Guidelines, Management and Treatment

8.2 Idiopathic Pulmonary Fibrosis Treatment Algorithm

9 IDIOPATHIC PULMONARY FIBROSIS - UNMET NEEDS

10 IDIOPATHIC PULMONARY FIBROSIS - KEY ENDPOINTS OF TREATMENT

11 IDIOPATHIC PULMONARY FIBROSIS - MARKETING PRODUCTS

11.1 List of Idiopathic Pulmonary Fibrosis Marketed Drugs Across the Top 7 Markets

11.1.1 Drug Name - Company Name

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 IDIOPATHIC PULMONARY FIBROSIS - PIPELINE DRUGS

12.1 List of Idiopathic Pulmonary Fibrosis Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name - Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. IDIOPATHIC PULMONARY FIBROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 IDIOPATHIC PULMONARY FIBROSIS - MARKET SCENARIO

- 14.1 Market Scenario - Key Insights
- 14.2 Market Scenario - Top 7 Markets
 - 14.2.1 Idiopathic Pulmonary Fibrosis - Market Size
 - 14.2.1.1 Market Size (2018-2023)
 - 14.2.1.2 Market Forecast (2024-2034)
 - 14.2.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies
 - 14.2.2.1 Market Size by Therapies (2018-2023)
 - 14.2.2.2 Market Forecast by Therapies (2024-2034)
- 14.3 Market Scenario - United States
 - 14.3.1 Idiopathic Pulmonary Fibrosis - Market Size
 - 14.3.1.1 Market Size (2018-2023)
 - 14.3.1.2 Market Forecast (2024-2034)
 - 14.3.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies
 - 14.3.2.1 Market Size by Therapies (2018-2023)
 - 14.3.2.2 Market Forecast by Therapies (2024-2034)
 - 14.3.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

14.4 Market Scenario - Germany

14.4.1 Idiopathic Pulmonary Fibrosis - Market Size

14.4.1.1 Market Size (2018-2023)

14.4.1.2 Market Forecast (2024-2034)

14.4.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies

14.4.2.1 Market Size by Therapies (2018-2023)

14.4.2.2 Market Forecast by Therapies (2024-2034)

14.4.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

14.5 Market Scenario - France

14.5.1 Idiopathic Pulmonary Fibrosis - Market Size

14.5.1.1 Market Size (2018-2023)

14.5.1.2 Market Forecast (2024-2034)

14.5.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies

14.5.2.1 Market Size by Therapies (2018-2023)

14.5.2.2 Market Forecast by Therapies (2024-2034)

14.5.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

14.6 Market Scenario - United Kingdom

14.6.1 Idiopathic Pulmonary Fibrosis - Market Size

14.6.1.1 Market Size (2018-2023)

14.6.1.2 Market Forecast (2024-2034)

14.6.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies

14.6.2.1 Market Size by Therapies (2018-2023)

14.6.2.2 Market Forecast by Therapies (2024-2034)

14.6.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

14.7 Market Scenario - Italy

14.7.1 Idiopathic Pulmonary Fibrosis - Market Size

14.7.1.1 Market Size (2018-2023)

14.7.1.2 Market Forecast (2024-2034)

14.7.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies

14.7.2.1 Market Size by Therapies (2018-2023)

14.7.2.2 Market Forecast by Therapies (2024-2034)

14.7.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

14.8 Market Scenario - Spain

14.8.1 Idiopathic Pulmonary Fibrosis - Market Size

14.8.1.1 Market Size (2018-2023)

14.8.1.2 Market Forecast (2024-2034)

14.8.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies

14.8.2.1 Market Size by Therapies (2018-2023)

14.8.2.2 Market Forecast by Therapies (2024-2034)

- 14.8.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
- 14.9 Market Scenario - Japan
 - 14.9.1 Idiopathic Pulmonary Fibrosis - Market Size
 - 14.9.1.1 Market Size (2018-2023)
 - 14.9.1.2 Market Forecast (2024-2034)
 - 14.9.2 Idiopathic Pulmonary Fibrosis - Market Size by Therapies
 - 14.9.2.1 Market Size by Therapies (2018-2023)
 - 14.9.2.2 Market Forecast by Therapies (2024-2034)
 - 14.9.3 Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

15 IDIOPATHIC PULMONARY FIBROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 IDIOPATHIC PULMONARY FIBROSIS MARKET - SWOT ANALYSIS

- 16.1 Strengths
- 16.2 Weaknesses
- 16.3 Opportunities
- 16.4 Threats

17 APPENDIX

I would like to order

Product name: Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/l68031F9ED84EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l68031F9ED84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

